Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-glucosidase inhibitors have enjoyed a high patient uptake in China owing to their long-standing market presence, physician comfort, and reimbursement through Category A of the NRDL. The dynamic access and reimbursement landscape of China has bolstered the uptake of newer drug classes—SGLT-2 inhibitors (such as dapagliflozin, canagliflozin, empagliflozin), GLP-1 receptor agonists (such as dulaglutide), and insulins (such as insulin degludec/insulin aspart)—through the inclusion of several high-performing agents in recent NRDL updates. Thus, the T2D market of China is expected to expand further over the 2020-2030 period, fueled by the increasing disease prevalence and an increasing uptake of novel agents that will boost overall market sales.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 endocrinologists
Diagnosed prevalence of T2D by country, with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key T2D therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 10+ drugs; Phase II: 5+ drugs; coverage of select preclinical and Phase I products